1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid and Adverse Drug Event

1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid has been researched along with Adverse Drug Event in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Berthelsen, AK; Brandt-Larsen, M; Brasso, K; Christensen, C; Holm, S; Højgaard, L; Kjaer, A; Klausen, TL; Kroman, N; Loft, A; Madsen, J; Nielsen, CH; Pappot, H; Persson, M; Ploug, M; Skovgaard, D; Thurison, T	1

Trials

1 trial(s) available for 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid and Adverse Drug Event

Article	Year
First-in-human uPAR PET: Imaging of Cancer Aggressiveness. Theranostics, 2015, Volume: 5, Issue:12 Topics: Breast Neoplasms; Copper Radioisotopes; Drug-Related Side Effects and Adverse Reactions; Female; Heterocyclic Compounds, 1-Ring; Humans; Male; Middle Aged; Molecular Imaging; Oligopeptides; Positron-Emission Tomography; Prognosis; Prostatic Neoplasms; Protein Binding; Receptors, Urokinase Plasminogen Activator; Urinary Bladder Neoplasms	2015

Article

Year

First-in-human uPAR PET: Imaging of Cancer Aggressiveness.

Theranostics, 2015, Volume: 5, Issue:12

Topics: Breast Neoplasms; Copper Radioisotopes; Drug-Related Side Effects and Adverse Reactions; Female; Heterocyclic Compounds, 1-Ring; Humans; Male; Middle Aged; Molecular Imaging; Oligopeptides; Positron-Emission Tomography; Prognosis; Prostatic Neoplasms; Protein Binding; Receptors, Urokinase Plasminogen Activator; Urinary Bladder Neoplasms

2015